retatrutide clinical trials status 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide approval: FDA status, clinical

People who are eligible to receive GLP-1 medications under the program will have a $50 copay

December 2024 Updates: Highmark: Sharon Regional Health System Update Please see the Highmark Announcement relevant to Membership within the Northeastern Pennsylvania region

8.7 Hepatic Impairment SYMLIN use has not been studied in patients with hepatic impairment [see Clinical Pharmacology (12.3)]

Peptide treatments should only be administered under the supervision of a qualified, licensed healthcare provider

The combined effect leads to improved glycaemic control and significant weight loss

Dietary optimization plays a huge role